The Antisera Market in the Czech Republic experienced notable fluctuations between 2013 and 2023, with values starting at $84.47 USD per capita in 2013 and reaching $105.75 USD per capita in 2023. Notable variations occurred; particularly, a sharp decline in 2014 and a surge in 2021. The market has demonstrated an average Compound Annual Growth Rate (CAGR) of approximately 1.7% over the last five years. Recent years show a stabilization trend after a strong growth period in 2021.

Future trends to watch for include:

Potential impacts of emerging health challenges on antisera demand.
Innovation in antibody production potentially driving efficiency and market expansion.
Regulatory changes impacting import and export within the EU affecting cost and supply chains.